Welcome and Introduction
Laquinimod – Treatment of Inflammatory Eye Disorders
Tasquinimod – Treatment of Multiple Myeloma
An Introduction to Multiple Myeloma
A Phase 1 Study of Tasquinimod in Patients with Relapsed or Refractory Multiple Myeloma
Naptumomab – Next generation immunotherapy capable of targeting cold tumors
Helén has a Ph.D in cell and molecular biology in Medical Science and more than 25 years of experience in leading drug development in senior positions.
Helena has a Ph.D in experimental hematology in Medical Science and has more than 25 years of experience in the pharmaceutical industry.
Adjunct professor of medicine at the University of Bonn, Germany.
Previous Head of Global Clinical R&D and Senior Vice President for Celgene.
Member of the Board at Active Biotech
Director, Abramson Cancer Center Clinical Research Unit and Associate Professor of Medicine at the University of Pennsylvania, US.
Principal Investigator Phase 1b/2a clinical study with Tasquinimod.
Asher is the CEO of Neotx Therapeutics, a clinical stage immunotherapy company. Since 2016, Active Biotech has a license agreement with NeoTX for the global development and commercialization of naptumomab for cancer treatment.